Exponent (EXPO) CEO Corrigan exercises RSUs and has shares withheld for taxes

Rhea-AI Filing Summary

Exponent Inc. President & CEO Catherine Corrigan reported routine equity compensation activity. On March 11, 2026, she exercised vested Restricted Stock Units covering 12,716 shares of common stock on a 1:1 basis, converting them into 12,716 shares of common stock at a stated price of $0.00 per share.

To satisfy tax withholding obligations tied to this vesting, 6,156 common shares were withheld by the company at a reference price of $70.03 per share, according to the filing footnotes. After these transactions, Corrigan directly holds 100,969 shares of Exponent common stock. This filing reflects compensation-related vesting and associated tax withholding, not an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corrigan Catherine

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M(1)		12,716	A	(2)	107,125	D
Common Stock	03/11/2026		F(3)		6,156	D	$70.03	100,969	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/11/2026		M(1)			12,716	03/11/2026	03/11/2026	Common Stock	12,716	(2)	0	D

Explanation of Responses:

1. Reflects the conversion of shares of vested Restricted Stock Units granted on March 11, 2022 into shares of Common Stock on a 1:1 basis.

2. Not applicable.

3. Reflects shares of common stock withheld by the Company to satify the tax withholding obligations of the Reporting Person.

	By: Wendy Whitehouse For: Catherine Corrigan	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Exponent (EXPO) CEO Catherine Corrigan report?

Catherine Corrigan reported exercising Restricted Stock Units for 12,716 shares of Exponent common stock. These RSUs vested from a March 11, 2022 grant and converted into common shares on a 1:1 basis as part of her equity compensation.

Did Exponent (EXPO) CEO Catherine Corrigan sell shares in this Form 4 filing?

The filing shows no open-market sale by Catherine Corrigan. Instead, 6,156 shares of common stock were withheld by Exponent to satisfy her tax withholding obligations related to the RSU vesting and exercise, which is treated differently from a discretionary market sale.

How many Exponent (EXPO) shares does CEO Catherine Corrigan own after this transaction?

Following the RSU exercise and tax withholding, Catherine Corrigan directly holds 100,969 shares of Exponent common stock. This total reflects her updated direct ownership after converting 12,716 RSUs and having 6,156 shares withheld by the company for taxes.

What type of securities were involved in Catherine Corrigan’s Exponent (EXPO) Form 4?

The Form 4 shows a derivative-to-common conversion. Corrigan exercised Restricted Stock Units, a form of stock-based compensation, converting 12,716 RSUs into 12,716 shares of Exponent common stock, followed by company share withholding to cover related tax liabilities.

Was the Exponent (EXPO) CEO’s Form 4 transaction compensation-related or an investment trade?

The transaction is compensation-related. It reflects the vesting and exercise of Restricted Stock Units granted on March 11, 2022, and company share withholding for taxes, rather than a discretionary open-market purchase or sale of Exponent shares by Catherine Corrigan.